Page 66 - Read Online

Page 14 of 14 Webster et al. J Cancer Metastasis Treat 2020;6:8 I http://dx.doi.org/10.20517/2394-4722.2019.38

38. Eremenco SL, Cella D, Arnold BJ. A comprehensive method for the translation and cross-cultural validation of health status
questionnaires. Eval Health Prof 2005;28:212-32.
39. Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, et al. Management of immunotherapy-related toxicities, version 1.2019. J
Natl Compr Canc Netw 2019;17:255-89.
40. Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with
cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med 2018;168:121-30.
41. Bajwa R, Cheema A, Khan T, Amirpour A, Paul A, et al. Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors
and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study. J Clin Med Res 2019;11:225-36.
42. Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, et al. Haematological immune-related adverse events induced by anti-
PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 2019;6:e48-e57.
43. Hryniewicki AT, Wang C, Shatsky RA, Coyne CJ. Management of immune checkpoint inhibitor toxicities: a review and clinical guideline
for emergency physicians. J Emerg Med 2018;55:489-502.
44. Khan S, Gerber DE. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review. Semin Cancer Biol 2019;
Epub ahead of print. doi: 10.1016/j.semcancer.2019.06.012.
45. Myers G. Immune-related adverse events of immune checkpoint inhibitors: a brief review. Curr Oncol 2018;25:342-7.
46. Teufel A, Zhan T, Hartel N, Bornschein J, Ebert MP, et al. Management of immune related adverse events induced by immune checkpoint
inhibition. Cancer Lett 2019;456:80-7.
47. Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol
2018;14:569-79.
48. Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and
ipilimumab. Ann Rheum Dis 2017;76:43-50.
49. Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 2018;19:345-61.
50. Tan MH, Iyengar R, Mizokami-Stout K, Yentz S, MacEachern MP, et al. Spectrum of immune checkpoint inhibitors-induced
endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabetes Endocrinol 2019;5:1.
51. Girotra M, Hansen A, Farooki A, Byun DJ, Min L, et al. The current understanding of the endocrine effects from immune checkpoint
inhibitors and recommendations for management. JNCI Cancer Spectr 2018;2:pky021.
52. Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am
J Clin Dermatol 2018;19:31-9.
53. Reddy HG, Schneider BJ, Tai AW. Immune checkpoint inhibitor-associated colitis and hepatitis. Clin Transl Gastroenterol 2018;9:180.
54. Benfaremo D, Manfredi L, Luchetti MM, Gabrielli A. Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors:
a review of the literature. Curr Drug Saf 2018;13:150-64.
55. Wang ZH, Shen L. Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors. Chronic Dis Transl Med
2018;4:1-7.
56. Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in
cancer patients. Eur Respir J 2017;50:pii: 1700050.
57. Mayo Clinic Website. Available from: https://www.mayoclinic.org/ [Last accessed on 4 Mar 2020]
58. Hansen AR, Ala-Leppilampi K, McKillop C, Siu LL, Bedard PL. Development of the functional assessment of cancer therapy-immune
checkpoint modulator (FACT-ICM): a scale to measure quality of life in cancer patients treated with ICMs. IASS J 2020; Epub ahead of
print. doi: 10.1002/cncr.32692.
59. Shaw SS, Jim HSL, Eisel S, Hoogland A, LeDuc D, et al. Patient reported toxicities: development and validation of patient-reported
symptom measure for lung cancer patients receiving immunotherapy. J Clin Oncol 2019;37:93.